HCPCS Code J0517: Injection, Benralizumab, 1 mg (Fasenra) Billing Guide

Key Takeaways

HCPCS Code J0517 describes injection, benralizumab, 1 mg – the J code for Fasenra (AstraZeneca), effective January 1, 2019.

Billing units equal the dose in milligrams: a 30 mg dose bills as 30 units; a 10 mg dose bills as 10 units under J0517.

Coverage code C (Carrier judgment) means Medicare reimbursement is not guaranteed – local MAC discretion applies, and prior authorization is required by most payers.

Pabau’s claims management software helps allergy and respiratory clinics track biologic administration, document medical necessity, and streamline J code submissions.

Billing errors on biologic injectables cost allergy and pulmonology practices more than they realize. A mismatched unit count, a missing modifier, or an incorrect NDC crosswalk can push a $4,000-per-dose Fasenra claim into denial – and recovery takes weeks. HCPCS Code J0517, which represents injection, benralizumab, 1 mg, is the code that governs every Fasenra administration claim in the United States. Getting it right means understanding how units map to package size, which modifiers CMS now requires, and how carrier judgment coverage affects your reimbursement odds.

This reference covers the complete billing picture for HCPCS Code J0517: code properties, billing units by package size, NDC codes, Medicare reimbursement structure, payer coverage requirements, administration codes, modifier rules, and the documentation practices that protect your claims. Refer to the current CMS Physician Fee Schedule for the most up-to-date ASP-based payment rates, which change quarterly.

HCPCS Code J0517: Definition, Code Properties, and Clinical Context

HCPCS Code J0517 is a Level II HCPCS code assigned and maintained by the Centers for Medicare and Medicaid Services (CMS) under the category “Drugs Administered Other Than Oral Method.” The code was added to the HCPCS system effective January 1, 2019, when benralizumab received its initial CMS recognition as a separately billable injectable biologic. The HCPCS action code is N (No maintenance for this code), meaning it requires no annual editorial update – the description is stable.

Benralizumab (brand name Fasenra, manufactured by AstraZeneca) is a monoclonal antibody that targets the interleukin-5 receptor alpha (IL-5Ra) subunit on eosinophil surfaces. By binding this receptor, it depletes circulating eosinophils, which drive airway and systemic inflammation. The FDA has approved benralizumab for two indications: (1) add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults and pediatric patients aged 6 years and older (pediatric expansion effective April 2024), and (2) treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in adult patients (approved September 2024). Severe eosinophilic asthma represents roughly 5-10% of all asthma patients but accounts for a disproportionate share of emergency visits and hospitalizations.

The standard HCPCS Code J0517 coverage code is C, designated as “Carrier judgment.” This is a critical distinction for billing teams: unlike codes with automatic Medicare coverage, J0517 reimbursement depends on local Medicare Administrative Contractor (MAC) discretion and whether the patient’s clinical presentation meets medical necessity criteria. Practices that administer Fasenra under the buy-and-bill model should verify MAC policies before administration, not after. Proper claims management workflows reduce the exposure that comes with carrier-discretion codes.

Billing Units and Package Sizes for J0517

The billing unit structure for HCPCS Code J0517 is straightforward but frequently causes errors when practices conflate vials with units. One billable unit equals one milligram of benralizumab. Because the standard Fasenra dose is either 30 mg or 10 mg depending on the formulation, the unit count differs by product.

AstraZeneca markets two primary formulations relevant to J0517 claims. The standard clinical dose for adults and pediatric patients weighing 35 kg or more is 30 mg, available as either a single-dose prefilled syringe or the FASENRA PEN autoinjector. The 10 mg/0.5 mL single-dose prefilled syringe is indicated for pediatric patients (ages 6-11) weighing under 35 kg, per FDA-approved weight-based dosing. Each requires a different unit count on the claim.

Billing the wrong unit count is among the most common J code errors. A practice that bills 3 units for a 30 mg dose (treating “1 vial” as the unit) will receive a fraction of the correct reimbursement – or trigger an automated claim edit. Always bill the milligram amount administered, not the number of syringes dispensed. This is confirmed by AstraZeneca’s myaccess360 coding resource and supported by payer medical policies from BCBSM and Moda Health.

NDC Codes and Product Identification for J0517

National Drug Codes (NDCs) are required on most Medicare and commercial payer claims for physician-administered drugs. For HCPCS Code J0517, the NDC crosswalk maps to three distinct Fasenra product presentations. Submitting an incorrect or outdated NDC can cause claim rejection even when the HCPCS code itself is correct.

Always verify the current NDC directly with AstraZeneca or through CMS NDC crosswalk files before billing, as NDC lot numbers and packaging configurations can change. The NDC format on claims uses the 5-4-2 digit structure (manufacturer-product-package), though some payers require the 11-digit format without hyphens.

• Fasenra 30 mg/mL single-dose prefilled syringe: NDC prefix 00310-1730-xx
• Fasenra 10 mg/0.5 mL single-dose prefilled syringe: NDC prefix 00310-1745-xx
• Fasenra 30 mg/mL single-dose autoinjector (FASENRA PEN): NDC prefix 00310-1830-xx

The “xx” suffix in each NDC represents the package code, which varies by lot. Payer medical policies from BCBSM and Moda Health confirm these NDC prefixes as of their most recent policy updates. Practices using the digital documentation tools within their practice management platform can embed NDC fields directly into administration records, reducing transcription errors at the time of claim submission. Cross-reference the dispensed NDC from your pharmacy invoice against this crosswalk before billing.

Buy-and-Bill vs. Specialty Pharmacy Pathways

Fasenra can reach the patient through two procurement channels, and the billing pathway differs significantly. Under buy-and-bill, the practice purchases benralizumab directly, administers it, and bills the drug plus administration under Medicare Part B or commercial insurance. Under the specialty pharmacy model, the payer directs the patient to an in-network specialty pharmacy, which ships the drug to the office; the practice bills only the administration code, not the drug itself.

Payer-specific formulary rules determine which pathway applies. Some commercial plans have moved Fasenra to a mandatory specialty pharmacy benefit, removing the buy-and-bill option entirely. Verify the applicable pathway at prior authorization to avoid purchasing drug inventory that a payer will not reimburse under Part B. Your medical office compliance protocols should include a pre-authorization step that captures the payer’s required procurement pathway before any Fasenra dose is ordered.

Medicare Reimbursement and Fee Schedule for J0517

Medicare Part B reimburses physician-administered drugs under the Average Sales Price (ASP) methodology. For HCPCS Code J0517, the reimbursement rate is calculated as ASP plus 6%, updated each calendar quarter based on manufacturer-reported pricing data. Because ASP fluctuates, no fixed annual rate applies – coders and billing managers must reference the current quarterly CMS Physician Fee Schedule to determine the payment amount in effect for the date of service.

Three pricing benchmarks appear in J0517 reimbursement discussions. Average Sales Price (ASP) is the CMS-preferred methodology and the basis for Medicare Part B payment. Wholesale Acquisition Cost (WAC) is the list price manufacturers charge wholesalers and is sometimes used by commercial payers when ASP data is unavailable. Average Wholesale Price (AWP) is an older benchmark, generally 20-25% above WAC, still referenced by some commercial contracts. Medicare always uses ASP plus 6%.

Because J0517 carries a carrier judgment coverage code, the MAC may require additional clinical documentation before approving payment. Practices should not assume that meeting the FDA-approved indication automatically satisfies the MAC’s medical necessity standard. Review the applicable Local Coverage Determination (LCD) or Local Coverage Article (LCA) for your MAC before billing. Accurate records kept in structured client records make it easier to produce this documentation on request.

Streamline Biologic Injection Billing with Pabau

Pabau's practice management platform helps allergy and respiratory clinics document biologic administrations, track J code claims, and maintain the prior authorization records needed to support J0517 reimbursement. See how Pabau handles drug administration workflows from pre-auth through claim submission.

Book a demo

Prior Authorization and Payer Coverage Criteria

Prior authorization (PA) is required by virtually every payer for HCPCS Code J0517 benralizumab claims. The PA process for biologics like Fasenra typically takes longer than for standard medications because payers require documented evidence of disease severity and failure of prior therapy. Submitting an incomplete PA can delay patient access by weeks while the practice resubmits documentation.

The documentation requirements for most payer PA reviews include the following clinical evidence:

• Confirmed diagnosis of severe persistent eosinophilic asthma (ICD-10-CM J45.50 or J45.51) or eosinophilic granulomatosis with polyangiitis (ICD-10-CM M30.1)
• Baseline blood eosinophil count meeting the payer threshold (commonly 150-300 cells/mcL or higher)
• Documentation of at least 12 months of high-dose inhaled corticosteroid therapy (plus a long-acting bronchodilator)
• Evidence of inadequate asthma control: exacerbations, oral corticosteroid use, or hospitalizations within the review period
• Failure of or contraindication to other anti-IL-5 biologics (required by some, not all, payers)

BCBSM and Moda Health publish detailed medical necessity criteria for Fasenra that map closely to these requirements. Commercial payer PA criteria shift annually with formulary updates, so practices should pull the current payer policy at the start of each plan year rather than relying on criteria from a prior authorization approved under a previous policy. The ACAAI (American College of Allergy, Asthma and Immunology) provides biologic administration coding guidance that practices can use alongside payer-specific requirements. Using automated workflows to track PA expiration dates prevents the lapse-and-denial scenario that affects many allergy clinics.

ICD-10 Diagnosis Codes Paired with J0517

The diagnosis codes submitted alongside HCPCS Code J0517 must reflect the FDA-approved indication. Using an unsupported ICD-10 code is grounds for claim denial and, in audit situations, potential recoupment. Only code the diagnoses documented in the medical record.

• J45.50 – Severe persistent asthma, uncomplicated
• J45.51 – Severe persistent asthma with (acute) exacerbation
• M30.1 – Polyarteritis with lung involvement (Churg-Strauss / EGPA) – valid primary diagnosis for the EGPA indication (FDA-approved September 2024)

Do not bill J0517 with mild or moderate asthma codes – benralizumab is approved only for the severe persistent phenotype for the asthma indication. Eosinophilic conditions under investigation for potential off-label benralizumab use (such as eosinophilic esophagitis) should not be coded as the primary diagnosis supporting a J0517 claim unless the payer has explicitly authorized off-label coverage in writing. Note that EGPA (M30.1) is now an FDA-approved on-label indication and can be billed as a primary diagnosis when supported by clinical documentation. Maintaining diagnosis-to-treatment documentation in structured clinical coding records protects the practice during payer audits.

Administration Codes, Modifiers, and Billing Workflow

Fasenra is administered as a subcutaneous injection. When billing the drug under HCPCS Code J0517, practices must also report the administration service separately using the appropriate CPT code. According to the ACAAI biologic administration coding guide, CPT code 96372 (therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular) is the applicable administration code for office-based benralizumab injections. Bill J0517 and 96372 on the same claim for the same date of service.

Modifier requirements for drug waste changed with CMS policy updates effective January 1, 2023. Both waste-related modifiers are now required when applicable.

• Modifier JW – Drug amount discarded/not administered to any patient. Report this modifier when a portion of a single-dose vial or syringe is discarded after administering the required dose. Accurate waste documentation is required to support the modifier.
• Modifier JZ – Zero drug amount discarded/not administered. Report this modifier when there is no discarded drug (i.e., the entire vial/syringe was administered). Effective January 1, 2023, CMS requires JZ on claims where no waste occurs – omitting it on a no-waste claim may trigger a compliance flag.

For Fasenra specifically, the standard dose (30 mg from a 30 mg/mL single-dose syringe) typically results in zero waste, meaning modifier JZ applies in most standard administration scenarios. When using the AAPC HCPCS code lookup to confirm current J0517 coding rules, verify that modifier guidance matches the current CMS policy year. Document the administered dose, lot number, NDC, and any waste in the administration record before closing the encounter. The prescription management tools in a modern practice management system can capture this data at the point of care, feeding directly into the billing record.

Step-by-Step J0517 Billing Workflow

1. Confirm prior authorization: Verify active PA approval and check that the current dose cycle falls within the approved authorization window.
2. Document medical necessity: Ensure the encounter note records the patient’s eosinophil count, asthma severity, and clinical rationale for continued biologic therapy.
3. Record NDC and lot number: Document the dispensed NDC and lot number from the product label at time of administration.
4. Calculate billable units: Bill 30 units of J0517 for a 30 mg dose; 10 units for a 10 mg dose. Do not bill per syringe.
5. Apply the correct modifier: Append modifier JZ (no waste) in standard full-dose administrations, or JW (waste) with supporting waste documentation if a partial dose is administered.
6. Bill administration code: Include CPT 96372 for the subcutaneous injection service on the same claim.
7. Submit with supporting diagnosis: Lead with J45.50 or J45.51 for the asthma indication, or M30.1 for the EGPA indication. Confirm the ICD-10 code matches the PA approval and the encounter documentation.

Verify the current ASP-based fee schedule rate for J0517 on the CMS HCPCS resources page before submitting Medicare claims. Also check PGM Billing’s HCPCS lookup tool to cross-reference the code’s current properties. Practices managing multiple biologic patients benefit from integrating compliance documentation checklists into their administration workflows, so nothing is missed between drug receipt and claim submission. The clinic dashboard in Pabau provides a centralized view of pending authorizations and submitted claims, reducing the manual follow-up burden on billing staff.

Expert Picks

Need to streamline your biologic drug billing process? Claims Management Software from Pabau helps allergy and pulmonology practices track J code submissions, manage prior authorization records, and reduce claim rejection rates for high-cost injectables.

Looking for guidance on documentation requirements for injectable therapies? Bupa CCSD Codes and Billing Guide covers structured billing approaches for specialty injectable procedures across different payer frameworks.

Want to reduce compliance risk on drug administration claims? Digital Forms in Pabau allow clinical staff to capture NDC, lot number, administered dose, and waste data at the point of care, building a defensible administration record before the claim is submitted.

Conclusion

Biologic injection billing is where documentation gaps turn into denial patterns. HCPCS Code J0517 requires accurate unit counts (1 unit = 1 mg), the correct waste modifier (JZ or JW), an active prior authorization, and a supported ICD-10 diagnosis – every element on every claim. Pabau’s claims management tools help allergy and respiratory practices build these checks into standard workflows, so J0517 submissions go out complete the first time.

To see how Pabau handles biologic administration documentation and J code billing from prior authorization through claim submission, book a demo with the team.

Frequently Asked Questions